Home › Sovrappeso › Arizona › Tucson
Studi clinici su Sovrappeso a Tucson, AZ
15 studi su Sovrappeso cercano partecipanti presso sedi a Tucson e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
In reclutamentoFase 3
- Synexus Clinical Research US, Inc./Orange Grove Family Practice, Tucson
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
In reclutamentoFase 3
- University of Arizona, Tucson
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
In reclutamentoFase 3
- Tucson Clinical Research Institute, Tucson
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
In reclutamentoFase 3
- Novak Clinical Research - Tucson - North La Cholla Boulevard, Tucson
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
In reclutamentoFase 3
- Research Site, Tucson
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
In reclutamentoFase 3
- Tucson Orthopaedic Institute - North Wyatt Drive, Tucson
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
In reclutamentoFase 2
- The Institute for Liver Health II dba Arizona Liver Health-Tucson, Tucson
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
In reclutamentoFase 3
- AURORA-1 Clinical Site, Tucson
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
In reclutamentoFase 3
- AURORA-2 Clinical Site, Tucson
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
In reclutamentoFase 3
- Arizona Clinical Trials, Tucson
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
In reclutamentoFase 3
- Arizona Clinical Trials, Tucson
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
In reclutamentoFase 3Volontari sani benvenuti
- ACCOMPLISH-2 Research Site, Tucson
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
In reclutamentoFase 2
- The Institute for Liver Health II dba Arizona Liver Health-Tucson, Tucson
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
In reclutamentoFase 2
- Pima Heart, Tucson
Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
In reclutamentoFase 3
- ACCOMPLISH-1 Research Site, Tucson
Studi su Sovrappeso in altre città
- San Antonio, TX34 studi
- Houston, TX33 studi
- Chicago, IL28 studi
- Orlando, FL27 studi
- Las Vegas, NV23 studi
- Miami, FL23 studi
- Atlanta, GA20 studi
- Dallas, TX20 studi
- New York City, NY19 studi
- Jacksonville, FL19 studi
- Washington, DC19 studi
- Austin, TX18 studi
Altri studi a Tucson
- Cancro al seno20 studi
- Cancro del polmone non a piccole cellule17 studi
- Obesità17 studi
- Cancro metastatico14 studi
- Cancro (tutti i tipi)12 studi
- Malattie cardiovascolari12 studi
- Cancro colorettale11 studi
- Cancro alla prostata11 studi
- Malattia epatica steatosica10 studi
- Insufficienza cardiaca10 studi
- Pressione alta10 studi
- Diabete di tipo 210 studi
Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.